Futility Analysis Supports Continued Evaluation of Cema-Cel in DLBCL

In an interview with Targeted Oncology, Jeff Sharman, MD, SCRI at Willamette Valley Cancer Institute & Research Center, discusses the rationale for the phase 2 ALPHA3 study (NCT06500273), detailing how interim futility findings support continued investigation of cemacabtagene ansegedleucel (cema-cel), an allogeneic chimeric antigen receptor (CAR) T-cell therapy, as consolidation therapy for patients with diffuse large B-cell lymphoma (DLBCL).

Read the full interview here.

Although many patients with DLBCL achieve durable remissions following standard chemoimmunotherapy, approximately 20% will ultimately relapse despite having a negative end-of-treatment PET/CT scan. Emerging minimal residual disease (MRD) assessment strategies using circulating tumor DNA (ctDNA) have demonstrated the ability to identify patients with molecular evidence of persistent disease who may be at increased risk for recurrence, creating an opportunity for risk-adapted post-treatment intervention.

The randomized phase 2 ALPHA3 study was designed to evaluate whether consolidation therapy with cema-cel can improve outcomes among patients with LBCL who achieve a PET-negative or otherwise observation-appropriate response after frontline chemoimmunotherapy but are found to be MRD-positive by ctDNA testing. Patients identified as molecularly high risk were randomized to either observation or treatment with cema-cel.

According to Sharman, the recently announced interim futility analysis focused primarily on determining whether the study should continue. Among the 24 evaluable patients included in the analysis—12 per treatment arm—MRD testing in the observation group generally demonstrated rising ctDNA levels, suggesting persistent or re-emerging disease. In contrast, 7 of 12 patients treated with cema-cel achieved MRD clearance. Two patients in the observation arm also experienced disease control, but the overall difference between groups exceeded 40 percentage points.

While longer follow-up is needed to determine whether MRD clearance translates into improved clinical outcomes such as relapse-free survival, the findings support the study’s underlying hypothesis and provide justification for continued enrollment and evaluation of cema-cel in this high-risk patient population.